Literature DB >> 8789503

Anal squamous cell cancer nodal metastases: prognostic significance and therapeutic considerations.

A M Cohen1, W D Wong.   

Abstract

Anal squamous cell cancers have regional lymph node spread to three sites: rectal mesentery, hypogastric, and inguinal. All such regional sites should be included in the initial radiation treatment fields and monitored for recurrence after the initial therapy.

Entities:  

Mesh：

Year:  1996        PMID： 8789503

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN： 1055-3207            Impact factor:   3.495


  5 in total

1.  Curatively resected isolated inguinal lymph node metastasis from cecum cancer: report of a case.

Authors:  Masayasu Hara; Hiroki Takahashi; Mikinori Sato; Satoru Takayama; Takaya Nagasaki; Hiromitsu Takeyama
Journal:  Surg Today       Date:  2012-10-31       Impact factor: 2.549

Review 2.  New approach to anal cancer: individualized therapy based on sentinel lymph node biopsy.

Authors:  Paola De Nardi; Michele Carvello; Carlo Staudacher
Journal:  World J Gastroenterol       Date:  2012-11-28       Impact factor: 5.742

3.  ACR Appropriateness Criteria®-Anal Cancer.

Authors:  Theodore S Hong; Jennifer L Pretz; Joseph M Herman; May Abdel-Wahab; Nilofer Azad; A William Blackstock; Prajnan Das; Karyn A Goodman; Salma K Jabbour; William E Jones; Andre A Konski; Albert C Koong; Miguel Rodriguez-Bigas; William Small; Charles R Thomas; Jennifer Zook; W Warren Suh
Journal:  Gastrointest Cancer Res       Date:  2014-01

Review 4.  Anal cancer treatment: current status and future perspectives.

Authors:  Marwan Ghosn; Hampig Raphael Kourie; Pamela Abdayem; Joelle Antoun; Dolly Nasr
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

5.  Anal adenocarcinoma requires prophylactic inguinal nodal treatment: Results from a single Chinese institution.

Authors:  Zhen Su; Zhan-Wen Guo; Yan-Ping Mao; Jie Tang; Xiao-Wen Lan; Fang-Yun Xie; Qun Li
Journal:  J Cancer       Date:  2017-04-09       Impact factor: 4.207
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.